Yield10 Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>YB</div>
YTEN -- USA Stock  

USD 9.37  0.26  2.85%

As many millenniums are trying to avoid basic materials space, it makes sense to outline Yield10 Bioscience a little further and try to understand its current market patterns. We are going to cover the possibilities of making Yield10 Bioscience into your portfolio. Is current Yield10 Bioscience value sustainable? We will go over the entity valuation drivers to give you a better outlook on taking a position in it.
Published over a month ago
View all stories for Yield10 Bioscience | View All Stories
Is Yield10 Bioscience (NASDAQ:YTEN) valuation reasonable?
This firm currently holds 3.73 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. The company has a current ratio of 8.21, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Our recommendation tool can cross-verify current analyst consensus on Yield10 Bioscience and to analyze the firm potential to grow in the current economic cycle.
We determine the current worth of Yield10 Bioscience using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Yield10 Bioscience based exclusively on its fundamental and basic technical indicators. By analyzing Yield10 Bioscience's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Yield10 Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Yield10 Bioscience. We calculate exposure to Yield10 Bioscience's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Yield10 Bioscience's related companies.

Yield10 Bioscience Investment Alerts

Yield10 investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Yield10 Bioscience performance across your portfolios.Please check all investment alerts for Yield10

Yield10 Bioscience Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Yield10 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Yield10 Bioscience competition to find correlations between indicators driving the intrinsic value of Yield10.

How Yield10 utilizes its cash?

To perform a cash flow analysis of Yield10 Bioscience, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Yield10 Bioscience is receiving and how much cash it distributes out in a given period. The Yield10 Bioscience cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Yield10 Bioscience Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (14.27 Million)

Acquisition by Anthony Sinskey of 660 shares of Yield10 Bioscience subject to Rule 16b-3

Legal trades by Yield10 Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Yield10 insider trading alert for grant of stock option (right to buy) by Anthony Sinskey, the corporate stakeholder, on 2nd of April 2021. This event was filed by Yield10 Bioscience Inc with SEC on 2021-04-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Yield10 Bioscience Investor Appetite?

Yield10 Bioscience reported the previous year's revenue of 744 K. Net Loss for the year was (14.41 M) with loss before overhead, payroll, taxes, and interest of (4.04 M).
 2015 2020 2021 (projected)
Receivables388 K215.05 K220.71 K
Inventories379 K435.85 K447.32 K

Margins Breakdown

Yield10 profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Yield10 Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Yield10 Bioscience profit margins.
7.67
Profit Margin
7.62
Operating Margin
10.36
EBITDA Margin
Operating Margin7.62
EBITDA Margin10.36
Gross Margin37.45
Profit Margin7.67


Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The latest value of Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is -10,157,103. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years. Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years.

Will Yield10 Bioscience latest rise continue?

Yield10 Bioscience latest mean deviation surges over 6.86. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Yield10 Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Yield10 Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Yield10 Bioscience

Whereas few other entities within the agricultural inputs industry are still a little expensive, even after the recent corrections, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. To summarize, as of the 13th of March 2021, our analysis shows that Yield10 Bioscience barely shadows the market. The company is undervalued and projects high chance of distress for the next 2 years. However, our latest 30 days buy-sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com